All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2023-12-04T16:43:01.000Z

ASH2023 abstracts: What’s hot in MPN?

By Oscar Williams
Dec 4, 2023
Share:

Bookmark this article

To help navigate the exciting content being presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in MPN.

Saturday, December 9

1792

Use of combination therapies Including the XPO1 inhibitor selinexor in is a potential effective therapeutic strategy to treat myelofibrosis patients

Min Lu

1794

Combinatorial BCL-2/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis

Giacomo Coltro

Sunday, December 10

619

Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: Pre-specified interim analysis of the randomized phase 2b ruxobeat clinical trial of the German Study Group for myeloproliferative neoplasms (GSG-MPN)

Steffen Koschmieder

620

Transform-1: a randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis

Naveen Pemmaraju

622

Selinexor plus ruxolitinib in JAK inhibitor (JAKi)-Naïve patients with myelofibrosis: long term follow up from XPORT-MF-034 suggestive of disease modification

Srinivas K. Tantravahi

628

Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, phase 3 study

Raajit K. Rampal

3158

Modulation of biomarkers by BET Inhibitor, BMS-986158, including JAK2 variant allele frequency (VAF), bone marrow (BM) fibrosis, and reversal of abnormal cytokine production in intermediate- or high-risk myelofibrosis (MF)

Si Tuen Lee-Hoeflich

3204

Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: Results from the phase 3 randomized FREEDOM2 study

Claire N Harrison

3207

Impact of symptom benefit and transfusion response on survival in myelofibrosis patients treated with pacritinib: PERSIST-2 landmark survival analysis

Helen Ajufo

Monday, December 11

746

Final analysis of the Daliah Trial: A randomized phase III trial of interferon-α versus hydroxyurea in patients with MPN

Trine Alma Knudsen

748

Impact of Cytoreductive drugs upon outcomes in a contemporary cohort of adolescent and young adults with essential thrombocythemia and polycythemia vera

Claire N Harrison

4533

Prognostic significance and clinical correlations of myeloid mutations in myelofibrosis based on their functional class

Paola Guglielmelli

5174

Effect of new or worsening anemia on clinical outcomes in 2233 patients with myelofibrosis treated with ruxolitinib in the Expanded-Access Jump study

Vikas Gupta

ASH 2023 Top Abstracts

Please click the button below to download the document

Download here

More about...
ASHEssential thrombocytosisHydroxyureaIFN-αJUMPMANIFEST-2MyelofibrosisMyeloproliferative neoplasmsNavitoclaxNCT01387763PelabresibPolycythemia veraRuxoBEATRuxolitinibSelinexorTRANSFORM-1XPORT-MF-034

Related articles

Add bookmark

Novel non-JAK inhibitors for MF: Updates from SOHO 2023

Here, we summarize the latest updates on novel non-JAK inhibitors currently being investigated for myelofibrosis, presented by Mascarenhas during the Society of Hematologic Oncology (SOHO) 2023...

Oct 4, 2023
Add bookmark

Novel non-JAK inhibitors for MF: Updates from SOHO 2023

Here, we summarize the latest updates on novel non-JAK inhibitors currently being investigated for myelofibrosis, presented by Mascarenhas...

Oct 4, 2023
Add bookmark

ASH 2022 abstracts: What’s hot in MPN?

To help navigate the exciting content presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub Steering Committee members provided their recommendations for the top...

Nov 30, 2022
Add bookmark

ASH 2022 abstracts: What’s hot in MPN?

To help navigate the exciting content presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub Steering Committee...

Nov 30, 2022

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox